NZ738862B2 - Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders - Google Patents
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disordersInfo
- Publication number
- NZ738862B2 NZ738862B2 NZ738862A NZ73886216A NZ738862B2 NZ 738862 B2 NZ738862 B2 NZ 738862B2 NZ 738862 A NZ738862 A NZ 738862A NZ 73886216 A NZ73886216 A NZ 73886216A NZ 738862 B2 NZ738862 B2 NZ 738862B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline free
- plate habit
- benzyloxy
- cyclopentyl
- disorders
- Prior art date
Links
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical class OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 title abstract 2
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- -1 (R)(7-(4-cyclopentyl (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indolyl)acetic acid Chemical compound 0.000 claims 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 238000000646 scanning calorimetry Methods 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000005748 tumor development Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
Abstract
The present invention relates to, inter alia, a novel crystalline free- plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy) -l,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) in the treatment of SIPI receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditionscharacterized byan underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic(e.g.,as may occur in inflammation, tumor development, and atherosclerosis).
Claims (7)
1. A crystalline free-plate habit of L-arginine salt of (R)(7-(4-cyclopentyl (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indolyl)acetic acid; 5 wherein said crystalline free-plate habit has a BET specific surface area of 0.1 m /g to 5.0 and wherein the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 ?, at: 8.2° ± 0.2°, 16.4° ± 0.2°, and 20.5° ± 0.2°. 10
2. The crystalline free-plate habit according to claim 1, having a BET specific surface area of 0.6 m /g to 4.0 m /g.
3. The crystalline free-plate habit according to claim 1 or claim 2, having a powder X-ray diffraction pattern comprising peaks, in terms of 2 ?, at: 8.2° ± 0.2°, 16.4° ± 0.2°, 20.5° ± 15 0.2°, and 24.6° ± 0.2°.
4. The crystalline free-plate habit according to any one of claims 1 to 3, having a powder X- ray diffraction pattern comprising peaks, in terms of 2 ?, at: 8.2° ± 0.2°, 16.4° ± 0.2°, 20.5° ± 0.2°, 24.6° ± 0.2°, 28.8° ± 0.2°, and 37.3° ± 0.2°.
5. The crystalline free-plate habit according to any one of claims 1 to 4, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0 °C to 208.5 °C at a scan rate of 10 °C/minute. 25
6. The crystalline free-plate habit according to any one of claims 1 to 4, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5 °C to 208.1 °C at a scan rate of 10 °C/minute.
7. The crystalline free-plate habit according to any one of claims 1 to 4, having a differential 30 scanning calorimetry trace conducted at a scan rate of 10 °C/minute comprising an endotherm substantially as depicted in any one of
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182841P | 2015-06-22 | 2015-06-22 | |
| US201562207531P | 2015-08-20 | 2015-08-20 | |
| PCT/US2016/038506 WO2016209809A1 (en) | 2015-06-22 | 2016-06-21 | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ738862A NZ738862A (en) | 2023-12-22 |
| NZ738862B2 true NZ738862B2 (en) | 2024-03-26 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007666A (en) | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluo romethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)a cetic acid(compound1) for use in sipi receptor-associated disorders. | |
| SG10201906876PA (en) | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | |
| WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| CO2018012655A2 (en) | Isoquinolin-3-yl-carboxamides, and preparation and use thereof | |
| JP2019516766A5 (en) | ||
| WO2019226213A3 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| EP4218404A3 (en) | Compositions and methods for producing tobacco plants and products having altered alkaloid levels | |
| BR112015014567A2 (en) | substituted pyridine-2-carboxamide compounds as inhibitors of apoptosis signal regulatory kinase | |
| CA2826751C (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| MX2016015435A (en) | Pharmaceutical combination comprising a class iii receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule edo-s101 together with its use in the treatment of cancer. | |
| EP3363797A8 (en) | Oral dosage form of apoptosis signal-regulating kinase inhibitors | |
| WO2011143423A3 (en) | Compounds useful as inhibitors of atr kinase | |
| MX2012013081A (en) | Compounds useful as inhibitors of atr kinase. | |
| MX2012013082A (en) | 2 -aminopyridine derivatives useful as inhibitors of atr kinase. | |
| WO2016176620A8 (en) | Extracellular matrix compositions for the treatment of cancer or immunological diseases | |
| MX2020009062A (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates. | |
| MX2015008543A (en) | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopro pyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline. | |
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| WO2015106200A3 (en) | Dipeptides as inhibitors of human immunoproteasomes | |
| NZ738862B2 (en) | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders | |
| WO2017034390A3 (en) | Bioactive swiftlet nest supplement | |
| AR090448A1 (en) | 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXYL] AMINO} -1- (R) -HYDROXYETHYL) -8-HYDROXYQUINOLIN-2 (1H) -ONA, HEMINAPADISILATE AS ADRENERGIC RECEIVER AGONIST b₂ | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
| MX2014003960A (en) | Template -fixed peptidomimetics as inhibitors of fpr1. | |
| MX2022006741A (en) | Hdac inhibitor solid state forms. |